1.10 USD
▲0.00+4.76%
2026-08-03
市值
$139.91M
市盈率
—
EPS
-1.08
股息率
—
52 周区间
0.78 – 4.98
成交量
1.37M
Beta
1.83
目标价
5.00
52W 低 0.7852W 高 4.98
价格走势
公司简介
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue...